Distinct pattern of synaptic loss in Parkinson’s disease depression and initial findings from the Yale Ketamine PD (KET-PD) trial
Objective: To investigate synaptic loss in Parkinson's Disease depression (PDd) using PET and [11C]UCB-J (a marker for synaptic density) and present the initial blinded findings…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study
Objective: To assess the feasibility of an aerobic exercise regimen in those with advanced PD and DBS. Background: Aerobic exercise is known to have beneficial…Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability
Objective: We performed a pilot study looking at the safety and tolerability of Faecal Microbiota Transplantation, its effect on the microbiome, and improvement of symptoms…One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion
Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs
Objective: To evaluate the membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD iPSCs in the presence and absence of extracellular α-Synuclein. Background:…Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
Objective: To summarize the rationale for LRRK2 inhibition in sporadic PD patients without LRRK2 mutations, and to describe the current design of the LUMA study,…Distinct Gut Microbiome in Parkinson’s disease Based on the Presence of Premotor Rapid-Eye Movement Sleep Behavior Disorders: Exploring the Alpha-synuclein
Objective: We aim to investigate the microbiome composition and functional profiles in Parkinson’s disease (PD) patients with and without premotor rapid eye movement sleep behavior…Increased Brain Free Water is Associated with Regional Gene Expression in Parkinson’s Disease
Objective: In this study, we used brain free water scores and regional gene expression profiles from the Allen Human Brain Atlas transcriptomic data to investigate…
- « Previous Page
- 1
- …
- 178
- 179
- 180
- 181
- 182
- …
- 436
- Next Page »